1. Beer TM, Eilers KM, Garzotto M, Egorin MJ, Lowe BA, Henner WD (2003a) Weekly high-dose calcitriol and docetaxel in metastatic androgen-independent prostate cancer. J Clin Oncol 21: 123–128
2. Beer TM, Garzotto M, Henner WD, Eilers KM, Wersinger EM (2003b) Intermittent chemotherapy in metastatic androgen-independent prostate cancer. Br J Cancer 89: 968–970
3. Cara S, Tannock IF (2001) Retreatment of patients with the same chemotherapy: implications for clinical mechanisms of drug resistance. Ann Oncol 12: 23–27
4. Eisenberger MA, de Wit R, Berry W, Bodrogi I, Pluzanska A, Chi K, Oudard S, Christine T, James N, Tannock I (2004) A multicenter phase III comparison of docetaxel (D)+prednisone (P) and mitoxantrone (MTZ)+P in patients with hormone-refractory prostate cancer (HRPC). Proc Am Soc Clin Oncol 23: 2
5. Petrylak DP, Tangen C, Hussain M, Lara PN, Jones J, Talpin ME, Burch P, Greene G, Small E, Crawford ED (2004) SWOG 99-16: randomized phase III trial of docetaxel (D)/estramustine (E) versus mitoxantrone (M)/prednisone (p) in men with androgen-independent prostate cancer (AIPCA). Proc Am Soc Clin Oncol 23: 2